Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.

Autor: Chalupka A; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria., Richter L; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.; Institute of Statistics, Graz University of Technology, Graz, Austria., Chakeri A; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.; Center for Public Health, Medical University Vienna, Vienna, Austria., El-Khatib Z; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria., Theiler-Schwetz V; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria., Trummer C; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria., Krause R; Department of Internal Medicine, Division of Infectious Diseases, Medical University of Graz, Graz, Austria., Willeit P; Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria.; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Vienna, Austria., Benka B; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria., Ioannidis JPA; Departments of Medicine, Epidemiology and Population Health, Biomedical Data Science, and Statistics and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA., Pilz S; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Jazyk: angličtina
Zdroj: European journal of clinical investigation [Eur J Clin Invest] 2024 Mar; Vol. 54 (3), pp. e14136. Date of Electronic Publication: 2023 Nov 30.
DOI: 10.1111/eci.14136
Abstrakt: Introduction: Evidence is limited on the effectiveness of a fourth vaccine dose against coronavirus disease 2019 (COVID-19) in populations with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We estimated the risk of COVID-19 deaths and SARS-CoV-2 infections according to vaccination status in previously infected individuals in Austria.
Methods: This is a nationwide retrospective observational study. We calculated age and gender adjusted Cox proportional hazard ratios (HRs) of COVID-19 deaths (primary outcome) and SARS-CoV-2 infections (secondary outcome) from 1 November to 31 December 2022, primarily comparing individuals with four versus three vaccine doses. Relative vaccine effectiveness (rVE) was calculated as (1-HR) X 100.
Results: Among 3,986,312 previously infected individuals, 281,291 (7,1%) had four and 1,545,242 (38.8%) had three vaccinations at baseline. We recorded 69 COVID-19 deaths and 89,056 SARS-CoV-2 infections. rVE for four versus three vaccine doses was -24% (95% CI: -120 to 30) against COVID-19 deaths, and 17% (95% CI: 14-19) against SARS-CoV-2 infections. This latter effect rapidly diminished over time and infection risk with four vaccinations was higher compared to less vaccinated individuals during extended follow-up until June 2023. Adjusted HR (95% CI) for all-cause mortality for four versus three vaccinations was 0.79 (0.74-0.85).
Discussion: In previously infected individuals, a fourth vaccination was not associated with COVID-19 death risk, but with transiently reduced risk of SARS-CoV-2 infections and reversal of this effect in longer follow-up. All-cause mortality data suggest healthy vaccinee bias.
(© 2023 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.)
Databáze: MEDLINE
Externí odkaz: